Compare ZURA & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZURA | SFST |
|---|---|---|
| Founded | 2022 | 1999 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.0M | 421.9M |
| IPO Year | N/A | 2012 |
| Metric | ZURA | SFST |
|---|---|---|
| Price | $7.00 | $52.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | $11.78 | ★ $64.00 |
| AVG Volume (30 Days) | ★ 448.8K | 61.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.76 |
| EPS | N/A | ★ 3.72 |
| Revenue | N/A | ★ $6,282,000.00 |
| Revenue This Year | N/A | $10.47 |
| Revenue Next Year | N/A | $12.19 |
| P/E Ratio | ★ N/A | $14.08 |
| Revenue Growth | N/A | ★ 12.99 |
| 52 Week Low | $0.99 | $29.80 |
| 52 Week High | $7.25 | $62.00 |
| Indicator | ZURA | SFST |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 35.33 |
| Support Level | $5.62 | $50.27 |
| Resistance Level | N/A | $52.60 |
| Average True Range (ATR) | 0.49 | 1.99 |
| MACD | -0.00 | -0.83 |
| Stochastic Oscillator | 79.20 | 14.20 |
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.